LIXT (Lixte Biotechnology Holdings, Inc. Common Stock) Stock Analysis - Politician Trades
Lixte Biotechnology Holdings, Inc. Common Stock (LIXT) is a publicly traded Healthcare sector company. As of May 21, 2026, LIXT trades at $5.60 with a market cap of $54.60M and a P/E ratio of 0.00. LIXT moved +1.90% today. Year to date, LIXT is +48.15%; over the trailing twelve months it is +327.48%. Its 52-week range spans $0.64 to $6.26. Rallies surfaces LIXT's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Which politicians traded LIXT stock?
Rallies tracks politician and congressional stock disclosures for LIXT, including purchases, sales, transaction dates, owners, and reported trade amounts when available.
Bernards Rene bought 5.53K (~$13.87K) on Oct 3, 2023.
van der Baan Bastiaan Jeroen bought 10.00K (~$28.00K) on Oct 3, 2023.
Bernards Rene bought 5.53K (~$13.87K) on Oct 3, 2023.
LIXT Analyst Consensus
LIXT analyst coverage data. Average price target: $0.00.
Common questions about LIXT
Which politicians traded LIXT stock?
Rallies tracks politician and congressional stock disclosures for LIXT, including purchases, sales, transaction dates, owners, and reported trade amounts when available.
Does Rallies track congressional trades in LIXT?
Yes. Rallies tracks politician and congressional stock disclosures for LIXT, including reported purchases, sales, dates, owners, and trade amounts when available.
Is LIXT research on Rallies investment advice?
No. Rallies provides research, data, and educational context for LIXT. It does not provide personalized investment advice.
